ArticleFrontiers in pharmacology2022
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Phenolic-Enriched Ethyl Acetate Fraction of Chatuphalatika Inhibits HMG-CoA Reductase and Preferentially Improves Hepatic Metabolic Parameters in High-Fat Diet-Fed Mice.Molecules (Basel, Switzerland) · 2026Article
- Compound Enzyme-Assisted Extraction and Characterization of Trigonella foenum-graecum L. Polysaccharides and Their Ameliorative Effects on MAFLD.Chemistry & biodiversity · 2026Article
- Protective role of hydroalcoholic extract ofResearch in pharmaceutical sciences · 2026Article
- From diet to disease modulation: the multi-targeted effects of medicinal-food homologous plants in hepatic fibrosis.Frontiers in nutrition · 2026Review
- Advanced Microbiome Therapeutics Accelerate MASLD Recovery by Restoring Intestinal Microbiota Equilibrium and the Gut-Liver Axis in a Mouse Model.Journal of agricultural and food chemistry · 2025Article
- The gut microbiota-mediated ferroptosis pathway: a key mechanism of ginsenoside Rd against metabolism-associated fatty liver disease.Chinese medicine · 2025Article
- Phyllanthi Fructus ameliorates hyperuricemia and kidney injure via inhibiting uric acid synthesis, modulating urate transporters, and alleviating inflammation.Scientific reports · 2024Article
- A Scoping Review on Hepatoprotective Mechanism of Herbal Preparations through Gut Microbiota Modulation.Current issues in molecular biology · 2024Article
- The impact of traditional Chinese medicine and dietary compounds on modulating gut microbiota in hepatic fibrosis: A review.Heliyon · 2024Review
- Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CClFrontiers in pharmacology · 2024Article
- Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites.Frontiers in pharmacology · 2024Article
- Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota.Frontiers in cellular and infection microbiology · 2024Review
- Review
- Genome ofFrontiers in plant science · 2023Article
- Investigation of the Therapeutic Effect of Total Alkaloids ofMetabolites · 2022Article
- Tandem mass tag-based proteomics analysis reveals the multitarget mechanisms ofFrontiers in pharmacology · 2022Article
- Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway.Frontiers in endocrinology · 2022Article
- Modulatory effect of camel milk on intestinal microbiota of mice with non-alcoholic fatty liver disease.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence suggests that dysregulation of the intestinal flora potentially contributes to the occurrence and development of nonalcoholic fatty liver disease (NAFLD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.